A RETROSPECTIVE ANALYSIS OF SECOND-LINE CHEMOTHERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)

被引：0
|
作者：
Bramati, A. [1 ]
Moretti, A. [1 ]
Garassino, M. C. [2 ]
Califano, R. [3 ]
Farina, G. [4 ]
Lo Dico, M. [5 ]
Cinquini, M. [6 ]
Michetti, G. N. [7 ]
Tiseo, M. [8 ]
Zucali, P. A. [9 ]
机构：
[1] AO Osped Fatebenefratelli Oftalmico, Milan, Italy
[2] Fatebenefratelli & Ophtalm Hosp, Milan, Italy
[3] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England
[4] Osped Fatebenefratelli Oftalmico, Milan, Italy
[5] Civil Hosp Livorno, Div Med Oncol, Livorno, Italy
[6] Mario Negri Inst Pharmacol Res, Milan, Italy
[7] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[8] Parma Hosp, Parma, Italy
[9] IRCCS, Ist Clin Humanitas, Dept Oncol, Rozzano, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S103 / S103
页数：1
相关论文
共 50 条
  • [21] Second-line treatment with pemetrexed following platinum based doublet chemotherapy in Malignant Pleural Mesothelioma
    Sorensen, J. B.
    Perell, K.
    Thielsen, A. K.
    EJC SUPPLEMENTS, 2005, 3 (02): : 337 - 337
  • [22] Single centre experience of the use of vinorelbine soft capsules as second-line therapy for patients with malignant pleural mesothelioma (MPM)
    Barfoot, J.
    Waite, K.
    Craik, K.
    LUNG CANCER, 2013, 79 : S33 - S33
  • [23] Second line chemotherapy in malignant pleural mesothelioma with oxaliplatin/gemcitabine
    Serke, Monika
    Xanthopoulos, Anastasios
    Bauer, Thorsten
    ANNALS OF ONCOLOGY, 2006, 17 : 231 - 231
  • [24] Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study
    Koda, Yuichi
    Kuribayashi, Kozo
    Doi, Hiroshi
    Kitajima, Kazuhiro
    Nakajima, Yasuhiro
    Ishigaki, Hirotoshi
    Nakamura, Akifumi
    Minami, Toshiyuki
    Takahashi, Ryo
    Yokoi, Takashi
    Kijima, Takashi
    ONCOLOGY, 2021, 99 (03) : 161 - 168
  • [25] Gemcitabine and cisplatin:: Second-line chemotherapy for malignant mesothelioma?: In reply
    Byrne, MJ
    Dewar, J
    van Hazel, G
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) : 2627 - 2627
  • [26] Evaluation of second line treatment of malignant pleural mesothelioma (MPM) at a large teaching hospital
    Williams, C.
    Appleton, E.
    Clarke, K.
    Franks, K.
    Snee, M.
    Jain, P.
    LUNG CANCER, 2020, 139 : S72 - S72
  • [27] Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
    Zhang, Dandan
    Liang, Jianping
    Lv, Yanhua
    Huang, Xikun
    Guo, Weihong
    MEDICINE, 2022, 101 (52) : E32459
  • [28] Outcomes of mesothelioma patients treated with second-line chemotherapy (SL): a retrospective analysis
    Cinquini, Michela
    Moretti, Anna
    Tiseo, Marcello
    Michetti, Luigi
    Lo Dico, Monica
    Follador, Alessandro
    Garassino, Marina C.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S754 - S755
  • [29] Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma
    Kim, Roger Y.
    Li, Yimei
    Marmarelis, Melina E.
    Vachani, Anil
    LUNG CANCER, 2021, 159 : 107 - 110
  • [30] Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients
    Porta, C
    Zimatore, M
    Bonomi, L
    Imarisio, I
    Paglino, C
    Sartore-Bianchi, A
    Mutti, L
    LUNG CANCER, 2005, 48 (03) : 429 - 434
12345